Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 13/20 | 0.56 |
| ▸ | ME1 | P48163 | 13/20 | 0.56 |
| ▸ | ME3 | Q16798 | 13/20 | 0.56 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23244289 | 1.00 | ME2 (0.56) | ME2ME1ME3CKS1BSKP1 | |
| SCHEMBL23244366 | 0.80 | TDP1 (0.63) | ME2ME1ME3CKS1BSKP1 | |
| SCHEMBL29576883 | 0.79 | ME2 (0.58) | ME2ME1ME3CKS1BSKP1 | |
| SCHEMBL23244158 | 0.79 | ME2 (0.58) | ME2ME1ME3CKS1BSKP1 | |
| SCHEMBL23244239 | 0.79 | ME2 (0.58) | ME2ME1ME3CKS1BSKP1 | |
| SCHEMBL23244261 | 0.76 | TDP1 (0.55) | ME2ME1ME3CKS1BSKP1 | |
| SCHEMBL21551525 | 0.75 | ME2 (0.66) | ME2ME1ME3HTTL3MBTL1 | |
| SCHEMBL23244220 | 0.74 | ME2 (0.62) | ME2ME1ME3HTTLMNA | |
| SCHEMBL23244270 | 0.74 | SIGMAR1 (0.64) | ME2ME1ME3LMNAMAPT | |
| SCHEMBL23259366 | 0.74 | SIGMAR1 (0.64) | ME2ME1ME3LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | ME2 2/4885ME1 1/4885ME3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.